Medingo’s new president and CEO to set up US operations
This article was originally published in Clinica
Executive Summary
Medingo (Yoqneam, Israel), a company that is about to launch its first product – an innovative insulin dispenser in the form of a skin patch plus remote control to direct levels of insulin delivered – has made Pete Wehrly president and CEO. He will also lead the setting up of operations in the US, replacing Ofer Yodfat in that role. Dr Yodfat will continue as general manager of Medingo Israel. Mr Wehrly is a veteran Medtronic executive with more than 20 years’ experience in the industry. Before joining the company, he was senior vice-president and president of Medtronic’s spinal and biologics division. The company has also appointed Kim Stebbings as vice-president of marketing. Ms Stebbings joins from Florida-based Anodyne Therapy (infrared light therapy) where she was vice-president of sales and marketing. She has more than 20 years’ experience as a medical technology sales and marketing executive.
You may also be interested in...
Asia Regulatory Forum Update
Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.
Saudi Arabia adopts interim device authorisation regulation
Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.
Canada takes action to increase more adverse event reporting
The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.